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Remote Ischemic Preconditioning Reduces Myocardial and Renal In-
jury After Elective Abdominal Aortic AneurysmRepair: A Randomized
Controlled Trial
Ali ZA, CallaghanCJ, LimE, et al. Circulation 2007;116(suppl I):I-98-105.
Conclusion: Remote ischemic preconditioning (RIPC) reduces post-
operative myocardial injury, myocardial infarction, and renal impairment in
patients undergoing elective open abdominal aortic aneurysm (AAA) repair.
Summary: Remote ischemic preconditioning is a phenomenon where
brief periods of ischemia, followed by reperfusion, can provide systemic
protection from prolonged ischemia. The authors sought to investigate
whether RIPC could reduce the incidence of myocardial and renal injury in
patients undergoing elective AAA repair. This was a randomized trial, and 82
patients were randomized to undergo AAA repair with RIPC or AAA repair
without RIPC. Remote ischemic preconditioning was performed using two
cycles of intermittent cross-clamping of the common iliac arteries with 10
minutes of ischemia, followed by 10 minutes of reperfusion. Cardiac tropo-
nin levels were used to assess postoperative myocardial injury andmyocardial
infarction. Renal injury was assessed by serum creatinine level. Baseline
characteristics were well matched in both groups.
The incidence of myocardial injury was reduced 27% by RIPC (39% vs
12%; 95% confidence interval [CI], 8.8%-45%; P  .005). Also reduced in
the RIPC patients were myocardial infarction (27% vs 5%; 95% CI, 7.3%-
38%; P  .006) and renal impairment (30% vs 7%; 95% CI, 6.4%-39%; P 
.009. The effect of covariables was assessed with multivariable analysis. The
protective effect of RIPC on myocardial injury (odds ratio, 0.22; 95% CI,
0.07-0.67; P  .008), myocardial infarction (odds ratio, 0.18; 95% CI,
0.04-0.75; P  .006) was independent of the covariables.
Comment: Studies suggest that ischemia at a site distal from the
heart can confer ischemic protection at remote sites. This must occur
through some sort of neural mechanism or a circulating humoral mech-
anism. It is intriguing to think that a simple maneuver that is feasible in
most AAA open repairs could reduce cardiac and renal impairment after
open AAA repair.
Transient Limb Ischemia Induces Remote Preconditioning and Re-
mote Postconditioning in Humans by a KATP Channel-Dependent
Mechanism
Loukogeorgakis SP, Williams R, Panagiotidou AT, et al. Circulation 2007;
116:1386-95.
Conclusion: Remote postconditioning (RPostC) is inducible by tran-
sient limb ischemia and is as effective as remote ischemic preconditioning
(RIPC) for preventing endothelial ischemic–reperfusion (IR) injury.
Summary: Ischemic postconditioning and ischemic preconditioning
are mechanisms that may protect tissues from injury during IR. In ischemic
preconditioning, short periods of IR are applied before a prolonged ischemic
insult. In ischemic postconditioning, there is a modified schedule of reper-
fusion that uses intermediate restoration of flow after prolonged episodes of
ischemia (Physiol Rev 2003;83:1113-51; Basic Res Cardiol 2005;100:295-
310). Both ischemic preconditioning and ischemic postconditioning share
similar mechanisms. In both forms of intervention, survival kinases and
mitochondrial adenosine triphosphate (ATP)-sensitive potassium (KATP)
channels are activated as part of the process of IR tissue protection. It is also
known that protection from IR injury can be achieved by application of
ischemia to remote sites during an injurious ischemic event. This is termed
remote postconditioning (RPostC).
In this study, the authors used an in vivo model of endothelial IR injury
to determine whether RPostC occurs in humans and if it shares similar
mechanisms with RIPC. The authors assessed endothelial function by flow-
mediated dilatation before and after 20minutes of arm ischemia, followed by
reperfusion. Remote ischemic preconditioning was induced by conditioning
cycles of 5 minutes of ischemia and reperfusion on the contralateral leg or
arm before IR. Remote postconditioning induction conditioning cycles
were administered during the ischemic phase of IR. The dependence of
RIPC and RPostC on KATP was determined with use of oral glibenclamide.
Ischemia–reperfusion reduced flow-mediated dilatation in healthy vol-
unteers (baseline, 9.3%  1.2% vs post-IR, 3.3%  0.7%; P  .0001).
Ischemia–reperfusion also caused a significant reduction in flow-mediated
dilatation in patients with atherosclerosis (baseline, 5.5% 0.6% vs post-IR,
2.3% 0.5%; P .01). These reductions were prevented by RIPC in healthy
volunteers (post-IR plus RIPC, 7.2%  0.5%, P  .0001 vs post-IR) and in
atherosclerotic patients (P .01 vs post-IR). Reduction was also prevented
by RPostC (post-IR plus RpostC, 8.0%  0.5%; P  .0001 vs post-IR).
Glibenclamide blocked the protective effects of both RPost C and RIPC.
Comment: The study may have huge implications. It suggests that in
patients undergoing an ischemic event (myocardial infarction, stroke, acute
mesentery ischemia or acute limb ischemia), the ischemia–reperfusion injury
may be modified by producing transient limb ischemia at a remote site
before and after revascularization of the critically ischemic tissue. It should
be possible to easily test the effect of this relatively benign stimulus on
patients with acute ischemic events.
Surgical Revascularization in Patients with End-Stage Renal Disease:
Results Using a New Paradigm in Outcomes Assessment
Jones WB, Cull DL, Kalbaugh CA, et al. Am Surg 2007;773:598-605.
Conclusion: If a multiparameter definition of success after surgical
revascularization in patients with end-stage renal disease is used, success is
achieved in only a minority of patients.
Summary:Quality of life and functional status considerations are now
being considered significant outcome variables in evaluations of any medical
intervention and are now added to simple observations regarding graft
patency and limb salvage as measures of success after surgical revasculariza-
tion for lower extremity arterial occlusive disease. In this study, the authors
propose a multiparameter definition of surgical success for revascularization
in patients with end-stage renal disease. Their definition of success included
maintenance of primary graft patency to the point of wound healing,
postoperative survival of at least 6 months, limb salvage of at least 1 year, and
maintenance of ambulatory status for at least 6 months. They used this
definition to evaluate success rates in their patients with end-stage renal
disease undergoing surgical revascularization. From 1998 to 2004, 52 limbs
in 40 patients with end-stage renal disease and tissue loss underwent surgical
revascularization in an attempt at limb salvage. At 36 months, secondary
graft patency was 54.7% and limb salvage was 53%. Using each of their four
components of surgical success separately, success ranged between 60%
(patent graft until wound healing) and 87.5% (survival for at least 6months).
When all parameters were combined, however, overall clinical success was
achieved in only 16 of 40 patients (40%). With multivariant analysis, coro-
nary artery disease was the only patient factor found to significantly reduce
clinical success (P  .04).
Comment: It makes sense that the more difficult your patient popula-
tion and the more parameters you include to define clinical success, the less
will be your clinical success rate. The results presented here involve param-
eters that matter to patients. They should prove useful in discussing therapy
for patients with end-stage renal disease and critical limb ischemia.
Randomized Clinical Trial of the Effect of Adding Subfascial Endo-
scopic Perforator Surgery to Standard Great Saphenous Vein Stripping
Kianifard B, Holdstock J, Allen C, et al. Brit J Surg 2007;94:1075-80.
Conclusion: Subfascial endoscopic perforator surgery (SEPS) as an
adjunct to standard varicose vein surgery reduces the number of incompe-
tent perforating veins at 1 year but has no effect on quality of life or varicose
vein recurrence at 1 year.
Summary: The authors sought to determine the fate of incompetent
perforating veins (IPVs) in patients undergoing standard varicose vein
surgery vs those treated with standard varicose vein surgery and SEPS.
Patients were included in this study if they were undergoing surgery for
varicose veins and had venous reflux (0.5 seconds) in the great saphenous
vein (GSV). All patients in the study also had IPVs. Patients were randomly
allocated to standard surgery (saphenofemoral ligation, stripping and phle-
bectomies alone) or standard surgery with the addition of SEPS. Patients
with recurrent varicose veins, deep venous reflux, deep venous thrombosis,
ulceration, or saphenopopliteal reflux were excluded. Incompetent perforat-
ing veins were determined by duplex ultrasound, preoperatively and at 1
week, 6 weeks, 6 months, and 1 year after surgery. Pain visual analogue
scores and quality of life questionnaires were obtained at the same time
periods.
There were 34 patients in the no SEPS group and 38 patients in the
SEPS group. The groups did not differ with respect to quality of life scores,
pain, or mobility during the follow-up period. At 1 year, there was a higher
proportion in the no SEPS vs SEPS group that had IPVs (25 of 32 vs 12 of
38; P  .001).
Comment: Dr John Harris of Stanford University once termed SEPS
“Surgery Escaping Proper Scrutiny.” Now, well more than a decade after its
introduction, there is still little in the way of evidence to definitively support
its use in the treatment of ulcerative or nonulcerative venous disease. Despite
what logically seems a pivotal role of IPVs in the production of venous
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